Total returns on $1000
1Y
- 3M
- 6M
- 1Y
- 3Y
- 5Y
Fund/benchmark | Change | |
---|---|---|
Price | RTW Biotech Opportunities Ltd (Ordinary Share) | +23.26% |
NAV | RTW Biotech Opportunities Ltd (Ordinary Share) | +16.07% |
Morningstar's Benchmark | (Russell 2000 Biotech Growth) 50.000% + ( Nasdaq Biotechnology Index) 50.000% | -- |
- Artiva Biotherapeutics prices IPO at $167 million
- Monthly Valuation Update and Factsheet
- Baroness Blackwood Appointed as Independent NED
- Investment in Mirador Therapeutics & Santa Ana Bio
- Total Voting Rights
- Positive Data Announcement - Avidity Biosciences
- Portfolio Company Numab Therapeutics Update
- Transaction in Own Shares
- Director Declaration
- Holding(s) in Company
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Shares outstanding | 335.71m |
---|---|
Market cap | 533.78m USD |
Total assets | 654.64m USD |
Total expense ratio | 1.97% |
High | 1.61 |
Low | 1.59 |
Previous close | 1.59 |
Average volume | 380.77k |
---|---|
YTD Change | +14.80% |
Beta | 0.6130 |
Diluted NAV (est) | 1.95 |
Diluted NAV (last pub) | 1.95 |
Premium/Discount | -17.44% |
Net Gearing | 0.00% |
Data delayed at least 20 minutes, as of Jul 25 2024 16:35 BST.
More ▼